Shots: Nanobiotix to receive a $20M up front and is eligible to receive ~$220 M as contingent payments and milestones along with royalties on net sales of NBTXR3 in the […]readmore
Tags : NBTXR3
Shots: The complete dose-finding part of P-Ib/II study assessed the safety, feasibility, and RP2D of NBTXR3 (intratumoral inj.) in 20 patients with LA (T3 to T4) or unresectable rectal cancer […]readmore